Endoscopic screening for gastrointestinal cancers

Precise estimates of the magnitude of benefits and harms of endoscopic screening for cancer are a prerequisite for informed decision making for or against participation in screening for individuals in the target population.

Photo: Colourbox

In the paper Do’s and don’ts in evaluation of endoscopic screening for gastrointestinal cancers published online first in the journal Endoscopy on Sept 21st, Michael Bretthauer and co-workers from the Clinical Effectiveness Research group outline the most common pitfalls in the evaluation of screening and offer recommendations for future studies.

Latest publications

Berg et al. 2020. Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases. Mol Oncol [Epub ahead of print] Flatin et al. 2020. Multiregional assessment of CIMP in primary colorectal cancers: phenotype concordance but marker variability. Int J Cancer [Epub ahead of print] Pilleron et al. 2020. Age disparities in stage-specific colon cancer survival across seven countries: an ICBP SURVMARK-2 population-based study. Int J Cancer [Epub ahead of print] Bergsland et al. 2020. Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open 5(6): e001040 Smeby et al. 2020. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine 59: 102923 All publications